| Literature DB >> 26588919 |
Rosanna Tortelli1, Massimiliano Copetti2, Simona Arcuti1, Marianna Tursi3, Annalisa Iurillo3, Maria Rosaria Barulli1, Rosa Cortese3, Rosa Capozzo1, Eustachio D'Errico3, Benoit Marin4,5,6, Isabella Laura Simone3, Giancarlo Logroscino7,8.
Abstract
The aim of this study is to investigate the frequency and the clinical correlations of pseudobulbar affect (PBA) in a population-based incident cohort of ALS patients. Incident ALS cases, diagnosed in 2011 and 2012, according to El Escorial criteria were enrolled from a prospective population-based registry in Apulia, Southern Italy. Neurological status was assessed using a standard neurological examination and the revised ALS Functional Rating Scale (ALSFRSr). The Center for Neurologic Study-Lability Scale (CNS-LS), a self-administered questionnaire, was used to evaluate the presence and severity of PBA. Total scores range from 7 to 35. A score ≥13 was used to identify the presence of PBA. One-hundred thirty-two sporadic incident ALS cases were enrolled. Median disease duration was 20 months (range 2-143), median onset-diagnosis interval (ODI) 12 months (range 2-131), median ALSFRSr at baseline 36/48 (range 2-47) and median ALSFRSr bulbar sub-score 10/12 (range 0-12). Neurological examination revealed presence of PBA in 34/132 patients (26%). Pathological CNS-LS score was found in 45/132 patients (34%). Median total CNS-LS score was 9/35 (range 7-29). The subgroup with pathological CNS-LS was characterized by a short disease duration from symptom onset, ODI, time to diffusion to a second region, time to generalization and ALSFRSr bulbar sub-score, bulbar onset, "definite" diagnostic category, bulbar upper motor-neuron involvement and presence of PBA at neurological examination. In population-based setting, one-third of ALS patients present PBA at diagnosis. The presence of PBA is associated with bulbar UMN involvement and markers of a more severe phenotype.Entities:
Keywords: Amyotrophic lateral sclerosis; Pseudobulbar affect
Mesh:
Year: 2015 PMID: 26588919 DOI: 10.1007/s00415-015-7981-3
Source DB: PubMed Journal: J Neurol ISSN: 0340-5354 Impact factor: 4.849